Nivolumab-associated digital small-vessel vasculitis in a patient with an advanced renal cell carcinoma

被引：12

作者：

Franco, Fernando ^{[1
]}

Mendez, Miriam ^{[1
]}

Gutierrez, Lourdes ^{[1
]}

Sanz, Jesus ^{[2
]}

Calvo, Virginia ^{[1
]}

Provencio, Mariano ^{[1
]}

机构：

[1] Puerta Hierro Univ Hosp, Dept Med Oncol, Majadahonda, Spain

[2] Puerta Hierro Univ Hosp, Dept Rheumatol, Majadahonda, Spain

来源：

IMMUNOTHERAPY | 2019年 / 11卷 / 05期

关键词：

immunotherapy; neoplasia; nivolumab; Raynaud's syndrome; renal carcinoma; vasculitis;

D O I：

10.2217/imt-2018-0082

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

The immunotherapy (IO) agents in the renal cell carcinoma represent the best option in the second line of treatment. However, these drugs can be associated with different types of toxicities. The vascular toxicity related with IO is very uncommon. We report a case of a 46-year-old man diagnosed with stage IV renal cell carcinoma. He received a second-line treatment with nivolumab. After the fourth cycle, he presented a small-vessel serious vasculitis associated with IO toxicity. He required treatment with corticosteroids and immunosuppressors for toxicity control. We speculate that the anti-PD-1 agents can generate a disproportionate vascular inflammatory process mediated by T cells. The data suggest that there is an intimate relationship between alterations in the PD-1/PD-L1 pathway and vasculitis.

引用

页码：379 / 384

页数：6

共 23 条

[1]

[Anonymous], CANC INFORM

[2]

[Anonymous], RMB OPEN

[3]

[Anonymous], BMJ CASE REP

[4] Checks and Balances in Autoimmune Vasculitis [J].

Cadena, Rebeca Hid ;

Abdulahad, Wayel H. ;

Hospers, G. A. P. ;

Wind, T. T. ;

Boots, Annemieke M. H. ;

Heeringa, Peter ;

Brouwer, Elisabeth .

FRONTIERS IN IMMUNOLOGY, 2018, 9

[5] Vasculitis associated with immune checkpoint inhibitors-a systematic review [J].

Daxini, Anisha ;

Cronin, Keri ;

Sreih, Antoine G. .

CLINICAL RHEUMATOLOGY, 2018, 37 (09) :2579-2584

[6] Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up [J].

Haanen, J. B. A. G. ;

Carbonnel, F. ;

Robert, C. ;

Kerr, K. M. ;

Peters, S. ;

Larkin, J. ;

Jordan, K. .

ANNALS OF ONCOLOGY, 2017, 28 :119-142

[7] 2012 Revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides [J].

Jennette, J. C. ;

Falk, R. J. ;

Bacon, P. A. ;

Basu, N. ;

Cid, M. C. ;

Ferrario, F. ;

Flores-Suarez, L. F. ;

Gross, W. L. ;

Guillevin, L. ;

Hagen, E. C. ;

Hoffman, G. S. ;

Jayne, D. R. ;

Kallenberg, C. G. M. ;

Lamprecht, P. ;

Langford, C. A. ;

Luqmani, R. A. ;

Mahr, A. D. ;

Matteson, E. L. ;

Merkel, P. A. ;

Ozen, S. ;

Pusey, C. D. ;

Rasmussen, N. ;

Rees, A. J. ;

Scott, D. G. I. ;

Specks, U. ;

Stone, J. H. ;

Takahashi, K. ;

Watts, R. A. .

ARTHRITIS AND RHEUMATISM, 2013, 65 (01) :1-11

[8] Immune Checkpoint Inhibitor Toxicity in 2018 [J].

Johnson, Douglas B. ;

Chandra, Sunandana ;

Sosman, Jeffrey A. .

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2018, 320 (16) :1702-1703

[9] Cerebral vasculitis mimicking intracranial metastatic progression of lung cancer during PD-1 blockade [J].

Laubli, Heinz ;

Hench, Jurgen ;

Stanczak, Michal ;

Heijnen, Ingmar ;

Papachristofilou, Alexandros ;

Frank, Stephan ;

Zippelius, Alfred ;

Stenner-Liewen, Frank .

JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2017, 5

[10] Onset of connective tissue disease following anti-PD1/PD-L1 cancer immunotherapy [J].

Le Burel, Sebastien ;

Champiat, Stephane ;

Routier, Emilie ;

Aspeslagh, Sandrine ;

Albiges, Laurence ;

Szwebel, Tali-Anne ;

Michot, Jean-Marie ;

Chretien, Pascale ;

Mariette, Xavier ;

Voisin, Anne-Laure ;

Lambotte, Olivier .

ANNALS OF THE RHEUMATIC DISEASES, 2018, 77 (03) :468-470

← 1 2 3 →